Benjamin Dastrup, MD
Ophthalmology · South Ogden, UTNPI 1073797809
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for ophthalmology clinicians in UT, where the typical reported total is $987.
Across 46 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147
- Alcon$146
- Apellis Pharmaceuticals, Inc.$94
- Bausch & Lomb Americas Inc.$92
- Aerie Pharmaceuticals, Inc.$89
- Dompe US, Inc.$86
- plus $407 from 10 others
Across 22 payments — averaging $17,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$377K
What the payments were for
- Food & beverage$1,060100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 6 | $147 |
| Alcon | 6 | $146 |
| Apellis Pharmaceuticals, Inc. | 4 | $94 |
| Bausch & Lomb Americas Inc. | 5 | $92 |
| Aerie Pharmaceuticals, Inc. | 5 | $89 |
| Dompe US, Inc. | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| NEW World Medical,inc. | 1 | $59 |
| Rxsight Inc | 1 | $56 |
| Amgen(2 entities) | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 3 | $54 |
| Ivantis, Inc | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $19 |
| Glaukos Corporation | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,060 in reported general payments places this provider in the 50th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $29,444 |
| Loteprednol Etabonate | 87 | $11,708 |
| LumiganBimatoprost | 20 | $11,493 |
| IlevroNepafenac | 23 | $8,618 |
| Prednisolone Acetate | 146 | $7,047 |
| Pred FortePrednisolone Acetate | 26 | $6,771 |
| Cyclosporine | 27 | $6,160 |
| Difluprednate | 36 | $4,789 |
| MoxifloxacinMoxifloxacin Hcl | 153 | $4,713 |
| RhopressaNetarsudil Mesylate | 12 | $3,835 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $2,949 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $2,370 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,366 |
| Brinzolamide | 15 | $2,162 |
| Latanoprost | 157 | $1,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $147 | $43,30370 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $89 | $3,83512 claims |
| AlconSimbrinza | $146 | $2,94915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in South Ogden
- Jesse SwiftSouth Ogden$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Phillip HoopesDraper$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.